Evidence map›Paper›PMID 32539826›Full record

ArticleInfectious diseases of poverty2020

Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya.

Bernard O Abudho, Bernard Guyah, Bartholomew N Ondigo, Eric M Ndombi, Edmund Ireri, Jennifer M Carter, Diana K Riner, Nupur Kittur, Diana M S Karanja, Daniel G Colley

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases of poverty, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The short-term impact ofProceedings. Biological sciences · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Bernard O AbudhoCentre for Global Health Research (KEMRI-CGHR), Kenya Medical Research Institute, Kisumu, Kenya. bernabu002@gmail.com.ORCID http://orcid.org/0000-0001-5176-325X
Bernard GuyahDepartment of Biomedical Sciences and Technology, Maseno University, Maseno, Kenya.
Bartholomew N OndigoCentre for Global Health Research (KEMRI-CGHR), Kenya Medical Research Institute, Kisumu, Kenya.
Eric M NdombiCentre for Global Health Research (KEMRI-CGHR), Kenya Medical Research Institute, Kisumu, Kenya.
Edmund IreriCentre for Clinical Research-Radiology Unit, Kenya Medical Research Institute, Nairobi, Kenya.
Jennifer M CarterCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA.
Diana K RinerCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA.
Nupur KitturCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA.
Diana M S KaranjaCentre for Global Health Research (KEMRI-CGHR), Kenya Medical Research Institute, Kisumu, Kenya.
Daniel G ColleyCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA.
University of Georgia · USKenya Medical Research Institute · KEMaseno University · KEEgerton University · KEKenyatta University · KE

Funding

Determinants of resistance in human schistosomiasisR01AI053695 · NIAID · UNIVERSITY OF GEORGIA (UGA) · PI COLLEY, DANIEL G · 2003 to 2014
$5.2M
NIAID NIH HHS R01 AI053695
6 · The paper itself

Abstract

backgroundWorld Health Organization guidelines recommend preventive chemotherapy with praziquantel to control morbidity due to schistosomiasis. The primary aim of this cross-sectional study was to determine if 4 years of annual mass drug administration (MDA) in primary and secondary schools lowered potential markers of morbidity in infected children 1 year after the final MDA compared to infected children prior to initial MDA intervention.

methodsBetween 2012 and 2016 all students in two primary and three secondary schools within three kilometers of Lake Victoria in western Kenya received annual mass praziquantel administration. To evaluate potential changes in morbidity we measured height, weight, mid-upper arm circumference, hemoglobin levels, abdominal ultrasound, and quality of life in children in these schools. This study compared two cross-sectional samples of Schistosoma mansoni egg-positive children: one at baseline and one at year five, 1 year after the fourth annual MDA. Data were analyzed for all ages (6-18 years old) and stratified by primary (6-12 years old) and secondary (12-18 years old) school groups.

resultsThe prevalence of multiple potential morbidity markers did not differ significantly between the egg-positive participants at baseline and those at 5 years by Mann Whitney nonparametric analysis and Fisher's exact test for continuous and categorical data, respectively. There was a small but significantly higher score in school-related quality of life assessment by year five compared to baseline by Mann Whitney analysis (P = 0.048) in 13-18 year olds where malaria-negative. However, anemia was not positively impacted by four annual rounds of MDA, but registered a significant negative outcome.

conclusionsWe did not detect differences in morbidity markers measured in a population of those infected or re-infected after multiple MDA. This could have been due to their relative insensitivity or a failure of MDA to prevent morbidity among those who remain infected. High malaria transmission in this area and/or a lack of suitable methods to measure the more subtle functional morbidities caused by schistosomiasis could be a factor. Further research is needed to identify and develop well-defined, easily quantifiable S. mansoni morbidity markers for this age group.

Indexed as

Mass Drug AdministrationAdolescentAnimalsChildCross-Sectional StudiesFemaleHumansKenyaMaleMorbidityPraziquantelPrevalenceSchistosoma mansoniSchistosomiasis mansoniSchistosomicidesPraziquantelSchistosomicidesKenyaMass drug administrationMorbiditySchistosomiasisSchool-basedSchool pediatrics quality of life scores

Identifiers

PMID32539826
PMCPMC7296924
OpenAlexW3034449427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.